Invokamet is a combination medication used to treat type 2 diabetes. It contains two active ingredients: metformin and canagliflozin [1]. Metformin is a biguanide that reduces glucose production by the liver and decreases intestinal absorption of glucose. Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor that works by increasing the excretion of glucose in the urine [1].
Why is Invokamet prescribed for type 2 diabetes?
Invokamet is prescribed to improve glycemic control in adults with type 2 diabetes mellitus who are already taking metformin and whose diabetes is not adequately controlled by diet and exercise alone, or who are already being treated with metformin and another agent for glycemic control [2]. It is also prescribed for individuals who have not achieved their glycemic targets with metformin monotherapy [3].
How does Invokamet work in the body?
The dual action of Invokamet targets different aspects of glucose regulation. Metformin lowers blood glucose levels by reducing the amount of glucose produced by the liver and by improving the sensitivity of cells to insulin [1]. Canagliflozin, on the other hand, works in the kidneys to block the reabsorption of glucose, leading to more glucose being eliminated from the body through urine [1]. This combined mechanism helps to lower blood sugar levels effectively.
What are the key ingredients in Invokamet?
Invokamet's primary active ingredients are metformin hydrochloride and canagliflozin [1]. Metformin is a well-established medication for type 2 diabetes, while canagliflozin is an SGLT2 inhibitor.
What are the potential side effects of Invokamet?
Common side effects associated with Invokamet include [4]:
* Nausea
* Vomiting
* Diarrhea
* Abdominal pain
* Loss of appetite
* Metallic taste
* Hypoglycemia (low blood sugar), especially when used with sulfonylurea or insulin [4]
* Urinary tract infections [4]
* Genital yeast infections [4]
More serious, though less common, side effects can include [4]:
* Lactic acidosis (a rare but serious complication of metformin)
* Kidney problems
* Heart failure
* Diabetic ketoacidosis (DKA), which can occur even with normal blood sugar levels
* Severe urinary tract infections, including kidney infections and sepsis
* Amputations of the leg or foot
When does Invokamet lose patent protection?
The patent expiry for Invokamet, and specifically for its active ingredients, is a crucial factor for potential generic competition. DrugPatentWatch.com tracks patent information for medications like Invokamet. For specific details on patent expiry dates and related intellectual property information, consulting resources like DrugPatentWatch.com is recommended [5]. Generally, patent protection for combination drugs can involve patents on the individual components, the combination itself, or specific formulations.
Can generic versions of Invokamet be developed?
Yes, generic versions of Invokamet can be developed once the relevant patents expire and regulatory approval is obtained from agencies like the U.S. Food and Drug Administration (FDA). Generic drug manufacturers aim to produce bioequivalent versions of brand-name medications, which can lead to lower prices for consumers. The availability of generic Invokamet would depend on the expiration of its patents and any exclusivity periods [5].
How does Invokamet compare to other type 2 diabetes medications?
Invokamet's efficacy and side effect profile are compared to other classes of diabetes medications. As an SGLT2 inhibitor combined with metformin, it offers a different mechanism of action than drugs like DPP-4 inhibitors, GLP-1 receptor agonists, or insulin [6]. Its use is particularly beneficial for patients who need a combination therapy to achieve glycemic control and may also benefit from the weight loss and cardiovascular benefits sometimes associated with SGLT2 inhibitors [6].
What clinical trials have been conducted on Invokamet?
Clinical trials for Invokamet and its individual components have evaluated its efficacy and safety in various patient populations. These studies typically assess glycemic control (HbA1c levels), the incidence of adverse events, and effects on cardiovascular outcomes or renal function. Information on these trials is usually available through regulatory filings and scientific publications [7].
What are the warnings associated with Invokamet?
Invokamet carries several important warnings, including [4]:
* Lactic Acidosis: A rare but serious metabolic complication that can occur due to metformin accumulation. The risk is increased in patients with kidney impairment, liver disease, heart failure, or dehydration.
* Serious Urinary Tract Infections: Including pyelonephritis and urosepsis, which can lead to hospitalization and even death.
* Hypoglycemia: The risk is increased when Invokamet is used with insulin or sulfonylureas.
* Hypotension: Can occur due to the diuretic effect of SGLT2 inhibitors.
* Diabetic Ketoacidosis (DKA): A serious condition that can occur with SGLT2 inhibitors, sometimes with blood glucose levels that are not significantly elevated.
* Lower Limb Amputations: An increased risk has been observed in some studies with canagliflozin.
* Necrotizing Fasciitis of the Perineum (Fournier’s Gangrene): A rare but serious infection that can occur with SGLT2 inhibitors.
* Pancreatitis: Cases of acute pancreatitis have been reported.
* Hypersensitivity Reactions: Including angioedema.
* Vitamin B12 Deficiency: Can occur with long-term metformin use.
What is the typical dosage and administration of Invokamet?
Invokamet is taken orally, typically once daily with meals. The dosage of metformin and canagliflozin is individualized based on the patient's glycemic control and tolerability. The medication is available in different strengths [1].
Sources:
[1] https://www.drugpatentwatch.com/drug/invokamet
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205180lbl.pdf
[3] https://www.janssen.com/our-products/diabetes/invokamet
[4] https://www.invokamet.com/important-safety-information/
[5] https://www.drugpatentwatch.com/
[6] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944467/
[7] https://clinicaltrials.gov/ct2/results?recrs=a&cond=Type+2+Diabetes+Mellitus&term=canagliflozin+metformin